File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: If concurrent–adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction–concurrent achieve better outcome?

TitleIf concurrent–adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction–concurrent achieve better outcome?
Authors
KeywordsNasopharyngeal carcinoma
Chemoradiotherapy
Concurrent-adjuvant
Induction-concurrent
Sequence
Issue Date2012
Citation
Journal of Radiation Oncology, 2012, v. 1 n. 2, p. 107-115 How to Cite?
AbstractIntroduction Radiotherapy (RT) is the primary treatment modality for nasopharyngeal carcinoma, and concurrent–adjuvant chemoradiotherapy (CA-CRT) is regarded as the standard of care for locally advanced disease after survival benefit was demonstrated by randomized clinical trials. However, there remain concerns about the exact magnitude of the benefit and tolerability by such an approach. Methods Through an extensive literature review, this paper provides an update on the available data on induction–concurrent chemoradiotherapy (IC-CRT) and a comparison with CA-CRT. Results Studies on IC-CRT show that tolerance and compliance to induction chemotherapy are better than adjuvant chemotherapy while the acute toxicity rates are similar. The reported failure-free rates and survival rates are encouraging for IC-CRT. However, part of the improvement might be attributed to better RT techniques, and the exact magnitude of benefit attributed to the induction phase remains uncertain. Conclusion The strategy with IC-CRT is an appealing option to be considered especially for patients with extensive locoregional disease infiltrating/abutting critical structures. Data from ongoing phase III trials will need to be available before the current standard of CA-CRT is at risk of being replaced.
Persistent Identifierhttp://hdl.handle.net/10722/220022
ISSN
2015 SCImago Journal Rankings: 0.215

 

DC FieldValueLanguage
dc.contributor.authorLee, WMA-
dc.contributor.authorNg, WT-
dc.contributor.authorChan, OH-
dc.contributor.authorSze, HK-
dc.date.accessioned2015-10-16T06:16:25Z-
dc.date.available2015-10-16T06:16:25Z-
dc.date.issued2012-
dc.identifier.citationJournal of Radiation Oncology, 2012, v. 1 n. 2, p. 107-115-
dc.identifier.issn1948-7894-
dc.identifier.urihttp://hdl.handle.net/10722/220022-
dc.description.abstractIntroduction Radiotherapy (RT) is the primary treatment modality for nasopharyngeal carcinoma, and concurrent–adjuvant chemoradiotherapy (CA-CRT) is regarded as the standard of care for locally advanced disease after survival benefit was demonstrated by randomized clinical trials. However, there remain concerns about the exact magnitude of the benefit and tolerability by such an approach. Methods Through an extensive literature review, this paper provides an update on the available data on induction–concurrent chemoradiotherapy (IC-CRT) and a comparison with CA-CRT. Results Studies on IC-CRT show that tolerance and compliance to induction chemotherapy are better than adjuvant chemotherapy while the acute toxicity rates are similar. The reported failure-free rates and survival rates are encouraging for IC-CRT. However, part of the improvement might be attributed to better RT techniques, and the exact magnitude of benefit attributed to the induction phase remains uncertain. Conclusion The strategy with IC-CRT is an appealing option to be considered especially for patients with extensive locoregional disease infiltrating/abutting critical structures. Data from ongoing phase III trials will need to be available before the current standard of CA-CRT is at risk of being replaced.-
dc.languageeng-
dc.relation.ispartofJournal of Radiation Oncology-
dc.subjectNasopharyngeal carcinoma-
dc.subjectChemoradiotherapy-
dc.subjectConcurrent-adjuvant-
dc.subjectInduction-concurrent-
dc.subjectSequence-
dc.titleIf concurrent–adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction–concurrent achieve better outcome?-
dc.typeArticle-
dc.identifier.emailLee, WMA: awmlee@hkucc.hku.hk-
dc.identifier.authorityLee, WMA=rp02056-
dc.identifier.doi10.1007/s13566-012-0032-0-
dc.identifier.hkuros265764-
dc.identifier.volume1-
dc.identifier.issue2-
dc.identifier.spage107-
dc.identifier.epage115-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats